Definition and classification
Melatonin–magnesium compound tablets combine melatonin with one or more magnesium salts in a tablet and may also contain vitamins, amino acids, botanical ingredients, and conventional excipients. This entry belongs to WSIC 3.1.4, Sleep Nutrition Supplements. Swallow tablets, chewables, orally disintegrating tablets, lozenges, and modified-release tablets are not equivalent dosage forms. The term compound tablet does not establish how a product should be taken or released.
Melatonin participates in circadian timing, while magnesium is required for many enzymes and neuromuscular functions. Placement in one tablet does not demonstrate synergy, and additional magnesium does not necessarily improve sleep in a person whose intake is already adequate. Product identity depends on the complete formula, dosage-form instructions, and regulatory category in the market of sale.
Magnesium salts, elemental magnesium, and labeling
Magnesium oxide, citrate, glycinate, and other salts differ in molecular mass, solubility, elemental-magnesium fraction, and gastrointestinal tolerance. The label should identify the compound and declare the nutritional amount as elemental magnesium. Total mass of the source salt is not the amount of magnesium delivered. When several salts are blended, every source and the combined elemental amount should remain traceable.
Melatonin should be stated per tablet and per serving, with tablets per serving, suggested daily amount, and timing distinguished. Extended-release, bilayer, and timed-release descriptions require supporting dissolution, release, and stability evidence; marketing terminology cannot convert an immediate-release tablet into a modified-release one. Magnesium and melatonin from other supplements, antacids, laxatives, and medicines also contribute to total exposure.
Sleep evidence and limits of interpretation
Melatonin may be useful for some jet lag, delayed sleep-wake phase, and selected sleep problems, but it is not a general treatment for every case of chronic insomnia. Randomized evidence for oral magnesium and sleep is inconsistent. Magnesium forms, elemental doses, populations, outcome measures, and study durations differ substantially, and current evidence does not support routine magnesium treatment of insomnia.
Direct trials of melatonin and magnesium together are few and often examine a specific delivery system or add zinc, vitamins, and other ingredients. A change in a questionnaire or actigraphy outcome in one formulation cannot separate the contribution of each constituent and does not validate an arbitrary tablet ratio. Improved self-reported sleep also does not rule out sleep apnea or another underlying disorder.
Tablet manufacturing and quality control
Manufacturing should establish identity, purity, strength, and relevant contaminant limits separately for melatonin and each magnesium salt. It must also validate uniform distribution of a low-dose melatonin ingredient within a much larger mineral formulation. Consistent tablet weight does not prove consistent melatonin content, and a correct elemental-magnesium calculation does not establish source identity or dissolution. Weighing, screening, blending, compression, coating, and packaging require batch records.
Finished-product testing addresses unit strength, content uniformity, hardness, friability, disintegration or release, microorganisms, and stability. A magnesium salt can affect moisture uptake, tablet bulk, compression, and disintegration, while a coating can change swallowing and release. Smooth appearance, thickness, and color do not verify active content. Splitting is appropriate only when instructions allow it and the divided-dose performance has been demonstrated.
Safety and interactions
Excess magnesium from supplements or medicines commonly causes diarrhea, nausea, and abdominal cramping. Reduced kidney function limits magnesium elimination and raises the risk of serious hypermagnesemia. Magnesium can interfere with absorption of some tetracycline and quinolone antibiotics and oral bisphosphonates. A pharmacist or clinician should determine spacing for the actual medicine rather than relying on a universal interval.
Melatonin can cause sleepiness, headache, dizziness, nausea, and reduced next-day alertness and may present concerns with anticoagulants, antiseizure medicines, and sedating products. Evaluation of a compound tablet must include both principal ingredients and every co-ingredient. Marked weakness, hypotension, altered consciousness, breathing difficulty, severe allergy, or persistent symptoms requires discontinuation and timely care.
Selection, storage, and use
Selection should focus on melatonin per tablet, elemental magnesium rather than total salt mass, dosage form, co-ingredients, batch identification, and expiration. Magnesium from both food and supplements matters to intake, but authorities define supplemental upper limits differently. A value from one jurisdiction should not be applied mechanically to every age, medical condition, and market.
Tablets should remain in their original package and be protected from moisture, heat, or light as labeled. Desiccants are not for ingestion. Moisture swelling, spots, musty odor, pronounced cracking, coating loss, or a failed seal are reasons not to use the product. It should be kept out of children's sight and reach and not mixed with routine medicines in an unlabeled container.
Suitability boundaries and care pathway
Kidney impairment, pregnancy or breastfeeding, childhood, older-adult polypharmacy, and planned surgery call for professional review. The same applies to use of antibiotics, bisphosphonates, anticoagulants, antiseizure medicines, or sedatives. Cramps, fatigue, and poor sleep are not specific diagnoses of magnesium deficiency, and symptoms alone cannot establish blood magnesium status or a need for supplementation.
Persistent insomnia, daytime impairment, snoring with gasping, restless legs, or unusual nighttime behavior requires assessment of the cause. A compound tablet cannot replace healthy sleep practices, cognitive behavioral therapy for insomnia, or treatment of an underlying condition. It should not be used to compensate for shift work, alcohol, caffeine, or chronic sleep restriction.